You are here

  • Home
  • Online First
  • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

Article metrics

Article menu

other Versions

Download PDFPDF
Clinical trial
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

 

Online download statistics by month:

Online download statistics by month: March 2022 to April 2024

AbstractFullPdf
Mar 20228102020
Apr 20226311316
May 20224461917
Jun 20227073821
Jul 2022343156
Aug 20222222014
Sep 2022249137
Oct 2022263148
Nov 202222255
Dec 202217921
Jan 202313464
Feb 202315573
Mar 202314365
Apr 20231361812
May 2023140136
Jun 202313023
Jul 20237521
Aug 20237232
Sep 20235742
Oct 202310234
Nov 202310240
Dec 202311144
Jan 202411963
Feb 20247612
Mar 20249686
Apr 20244132
Total5761249174